Fig. 1. A-1210477 in combination with ABT-263 reduced cell viability and induced apoptosis in melanoma cells, in monolayer conditions.

a ATP assays of six melanoma cell lines upon indicated treatments for 48 h. The viability of the DMSO control for each cell line was set to 100%. The combination significantly (p ≤ 0.01) reduced cell viability compared with DMSO or with single drug treated conditions in all melanoma cell lines. For clarity, we marked only the combinational treatments that were significantly different from comparisons with the DMSO and the single drug treatments. Within each significant combination treatment, we only show the least significant p-value of the comparisons. * indicates p < 0.05; ** indicates p < 0.01; *** indicates p < 0.001. b Cells were treated for 48 h of control (DMSO), 5 μM A-1210477, 3.3 μM ABT-263 or the combination of 5 μM A-1210477 plus 3.3 μM ABT-263, and then subjected to Immunoblot with an antibody recognizing full length and cleaved PARP. The combination treatment increased the cleaved: full-length PARP ratio in all lines. Molecular weight markers are in kDa